First Time Loading...

Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 11.42 CAD 2.06% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

PRN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free a... [ Read More ]

The intrinsic value of one PRN stock under the Base Case scenario is 7.24 CAD. Compared to the current market price of 11.42 CAD, Profound Medical Corp is Overvalued by 37%.

Key Points:
PRN Intrinsic Value
Base Case
7.24 CAD
Overvaluation 37%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Profound Medical Corp

Backtest PRN Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling PRN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

TULSA's Progress and Expansion in Prostate Treatment
2023-Q4 Earnings Call

TULSA's Progress and Expansion in Prostate Treatment

In 2023, the groundwork for TULSA as a mainstream prostate cancer treatment was solidified, achieving a significant presence in top US cancer centers. TULSA's installed base is projected to grow to 75 by end-2024. Gaining new CPT codes, TULSA anticipates favorable Medicare reimbursement starting January 2025. Technological advances include FDA's clearance of the Thermal Boost AI module and a pending Contouring Assistant module. The collaboration with Siemens Healthineers aims to deliver a comprehensive diagnostic and interventional MR solution. The company has witnessed 60% growth and expects more, though specific revenue guidance for 2024 wasn't provided.

Financials

Balance Sheet Decomposition
Profound Medical Corp

Current Assets 41.9m
Cash & Short-Term Investments 26.2m
Receivables 7.3m
Other Current Assets 8.4m
Non-Current Assets 2m
PP&E 1.5m
Intangibles 490k
Current Liabilities 6.4m
Accounts Payable 3.3m
Other Current Liabilities 3.1m
Non-Current Liabilities 6.4m
Long-Term Debt 5.6m
Other Non-Current Liabilities 787k
Efficiency

Earnings Waterfall
Profound Medical Corp

Revenue
7.2m USD
Cost of Revenue
-2.8m USD
Gross Profit
4.4m USD
Operating Expenses
-33m USD
Operating Income
-28.6m USD
Other Expenses
47k USD
Net Income
-28.6m USD

Free Cash Flow Analysis
Profound Medical Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

PRN Profitability Score
Profitability Due Diligence

Profound Medical Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
Positive 1-Year Revenue Growth
Negative 3-Years Revenue Growth
23/100
Profitability
Score

Profound Medical Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

PRN Solvency Score
Solvency Due Diligence

Profound Medical Corp's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
High Altman Z-Score
Low D/E
69/100
Solvency
Score

Profound Medical Corp's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PRN Price Targets Summary
Profound Medical Corp

Wall Street analysts forecast PRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRN is 16.38 CAD with a low forecast of 14.26 CAD and a high forecast of 18.9 CAD.

Lowest
Price Target
14.26 CAD
25% Upside
Average
Price Target
16.38 CAD
43% Upside
Highest
Price Target
18.9 CAD
65% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

PRN Price
Profound Medical Corp

1M 1M
-9%
6M 6M
-16%
1Y 1Y
-11%
3Y 3Y
-53%
5Y 5Y
+43%
10Y 10Y
+9 830%
Annual Price Range
11.42
52w Low
9.68
52w High
19.87
Price Metrics
Average Annual Return 33.67%
Standard Deviation of Annual Returns 68.3%
Max Drawdown -88%
Shares Statistics
Market Capitalization 279m CAD
Shares Outstanding 24 428 900
Percentage of Shares Shorted 0.94%

PRN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Profound Medical Corp Logo
Profound Medical Corp

Country

Canada

Industry

Health Care

Market Cap

279m CAD

Dividend Yield

0%

Description

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Contact

ONTARIO
Mississauga
2400 Skymark Ave Unit 6
+16474761350.0
http://www.profoundmedical.com

IPO

2014-09-24

Employees

146

Officers

Chairman of the Board & CEO
Dr. Arun Swarup Menawat MBA, Ph.D.
Chief Financial Officer
Mr. Rashed Dewan
Chief Commercial Officer of Outside US
Mr. Hartmut Warnken
Senior Vice President of Product Leader TULSA-PRO
Dr. Mathieu Burtnyk
Chief Commercial Officer of US
Mr. Abbey Goodman
Investor Relations
Mr. Stephen Kilmer
Show More
Senior VP & Product Leader Sonalleve
Mr. Jacques F. Cornet
Assistant Corporate Controller
Mr. Matthew Sobczyk C.A., CPA
Software Developer
Mr. Levant Tinaz
Show Less

See Also

Discover More
What is the Intrinsic Value of one PRN stock?

The intrinsic value of one PRN stock under the Base Case scenario is 7.24 CAD.

Is PRN stock undervalued or overvalued?

Compared to the current market price of 11.42 CAD, Profound Medical Corp is Overvalued by 37%.